Kikuta Atsushi
Department of Pediatric Oncology, Fukushima Medical University.
Rinsho Ketsueki. 2021;62(8):1256-1264. doi: 10.11406/rinketsu.62.1256.
Sinusoidal obstruction syndrome (SOS), also called veno-occlusive disease (VOD) of the liver, is one of the most relevant complications of hepatic sinusoidal endothelial origin that appears early after hematopoietic cell transplantation (HCT). Despite its relatively low incidence and the spontaneous resolution of most SOS/VOD cases, severe SOS/VOD evolved to multi-organ failure with an >80% mortality rate and represents one of the major clinical problems after HCT. The sinusoidal endothelial cells and hepatocytes are damaged by toxic metabolites generated by the conditioning regimen in these patients. Several risk factors have been identified for SOS/VOD development. Although defibrotide is recommended for both prevention and treatment, no satisfactory therapy exists for managing severe SOS/VOD. Thus, this review describes the new definition of SOS/VOD diagnosis and the severity grading of suspected SOS/VOD from the European Society for Blood and Marrow Transplantation. Furthermore, it describes the results of current treatment including the Japanese therapeutic use program, defibrotide treatment protocol.
窦性阻塞综合征(SOS),也称为肝静脉闭塞病(VOD),是造血细胞移植(HCT)后早期出现的最相关的肝窦内皮源性并发症之一。尽管其发病率相对较低,且大多数SOS/VOD病例可自发缓解,但严重的SOS/VOD会发展为多器官功能衰竭,死亡率超过80%,是HCT后的主要临床问题之一。这些患者的预处理方案产生的毒性代谢产物会损害肝窦内皮细胞和肝细胞。已确定了几个SOS/VOD发生的危险因素。尽管推荐去纤苷用于预防和治疗,但对于严重的SOS/VOD尚无令人满意的治疗方法。因此,本综述描述了欧洲血液和骨髓移植学会对SOS/VOD诊断的新定义以及疑似SOS/VOD的严重程度分级。此外,还描述了包括日本治疗应用方案、去纤苷治疗方案在内的当前治疗结果。